CLAIMS:

1. A pharmaceutical composition comprising (i) a therapeutically effective amount of at least one spliceosome modulator and (ii) a therapeutically effective amount of at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors.
2. The pharmaceutical composition of claim 1, wherein the at least one spliceosome modulator is chosen from pladienolide derivatives.
3. The pharmaceutical composition of claim 1 or claim 2, wherein the at least one spliceosome modulator is chosen from E7107, H3B-8800, and pharmaceutically acceptable salts thereof.
4. The pharmaceutical composition of any one of claims 1-3, wherein the at least one spliceosome modulator is chosen from E7107 and pharmaceutically acceptable salts thereof.
5. The pharmaceutical composition of any one of claims 1-3, wherein the at least one spliceosome modulator is chosen from H3B-8800 and pharmaceutically acceptable salts thereof.
6. The pharmaceutical composition of any one of claims 1-5, wherein the at least one spliceosome modulator is stereoisomerically pure.
7. The pharmaceutical composition of any one of claims 1-5, wherein the at least one spliceosome modulator comprises greater than about 80% by weight of one stereoisomer.
8. The pharmaceutical composition of any one of claims 1-5, wherein the at least one spliceosome modulator comprises greater than about 90% by weight of one stereoisomer.
9. The pharmaceutical composition of any one of claims 1-5, wherein the at least one spliceosome modulator comprises greater than about 95% by weight of one stereoisomer.
10. The pharmaceutical composition of any one of claims 1-5, wherein the at least one spliceosome modulator comprises greater than about 97% by weight of one stereoisomer.

11. The pharmaceutical composition of any one of claims 1-10, wherein the at least one inhibitor is chosen from HA14-1, BH3I-1, antimycin A, chelerythrine, gossypol (NSC19048), apogossypol (NSC736630), TW-37, 4-(3-methoxy-phenylsulfonyl)-7-nitro-benzofuran-3-oxide (MNB), TM12-06, obatoclax (GX15-070), venetoclax (ABT199), navitoclax (ABT263), A-1331852, ABT737, and pharmaceutically acceptable salts thereof.
12. The pharmaceutical composition of any one of claims 1-11, wherein the at least one inhibitor is chosen from venetoclax (ABT199), navitoclax (ABT263), A-1331852, ABT737, and pharmaceutically acceptable salts thereof.
13. The pharmaceutical composition of any one of claims 1-12, wherein the at least one inhibitor is chosen from venetoclax (ABT199) and pharmaceutically acceptable salts thereof.
14. The pharmaceutical composition of any one of claims 1-12, wherein the at least one inhibitor is chosen from navitoclax (ABT263) and pharmaceutically acceptable salts thereof.
15. The pharmaceutical composition of any one of claims 1-12, wherein the at least one inhibitor is chosen from ABT737 and pharmaceutically acceptable salts thereof.
16. The pharmaceutical composition of any one of claims 1-12, wherein the at least one inhibitor is chosen from A-1331852 and pharmaceutically acceptable salts thereof.
17. The pharmaceutical composition of any one of claims 1-16, wherein the at least one spliceosome modulator is formulated for intravenous, oral, subcutaneous, or intramuscular administration.
18. The pharmaceutical composition of any one of claims 1-17, wherein the at least one spliceosome modulator is formulated for oral administration.
19. The pharmaceutical composition of any one of claims 1-18, wherein the at least one inhibitor is formulated for intravenous, oral, subcutaneous, or intramuscular administration.

20. The pharmaceutical composition of any one of claims 1-19, wherein the at least one inhibitor is formulated for oral administration.
21. A combination comprising (i) at least one spliceosome modulator and (ii) at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors, for use in the treatment of cancer, wherein the at least one spliceosome modulator is to be administered simultaneously, separately, or sequentially with the at least one inhibitor.
22. Use of a combination comprising (i) at least one spliceosome modulator and (ii) at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors, in the manufacture of a medicament for the treatment of cancer, wherein the at least one spliceosome modulator is to be administered simultaneously, separately, or sequentially with the at least one inhibitor.
23. The use of claim 22, wherein the at least one spliceosome modulator is chosen from pladienolide derivatives.
24. The use of claim 22 or claim 23, wherein the at least one spliceosome modulator is chosen from E7107, H3B-8800, and pharmaceutically acceptable salts thereof.
25. The use of any one of claims 22-24, wherein the at least one spliceosome modulator is chosen from E7107 and pharmaceutically acceptable salts thereof.
26. The use of any one of claims 22-24, wherein the at least one spliceosome modulator is chosen from H3B-8800 and pharmaceutically acceptable salts thereof.
27. The use of any one of claims 22-24, wherein the at least one spliceosome modulator is stereoisomerically pure.
28. The use of any one of claims 22-24, wherein the at least one spliceosome modulator comprises greater than about 80% by weight of one stereoisomer.

29. The use of any one of claims 22-24, wherein the at least one spliceosome modulator comprises greater than about 90% by weight of one stereoisomer.
30. The use of any one of claims 22-24, wherein the at least one spliceosome modulator comprises greater than about 95% by weight of one stereoisomer.
31. The use of any one of claims 22-24, wherein the at least one spliceosome modulator comprises greater than about 97% by weight of one stereoisomer.
32. The use of any one of claims 22-31, wherein the at least one inhibitor is chosen from HA14-1, BH3I-1, antimycin A, chelerythrine, gossypol (NSC19048), apogossypol (NSC736630), TW-37, 4-(3-methoxy-phenylsulfonyl)-7-nitro-benzofuran-3-oxide (MNB), TM12-06, obatoclax (GX15-070), venetoclax (ABT199), navitoclax (ABT263), A-1331852, ABT737, and pharmaceutically acceptable salts thereof.
33. The use of any one of claims 22-32, wherein the at least one inhibitor is chosen from venetoclax (ABT199), navitoclax (ABT263), A-1331852, ABT737, and pharmaceutically acceptable salts thereof.
34. The use of any one of claims 22-33, wherein the at least one inhibitor is chosen from venetoclax (ABT199) and pharmaceutically acceptable salts thereof.
35. The use of any one of claims 22-33, wherein the at least one inhibitor is chosen from navitoclax (ABT263) and pharmaceutically acceptable salts thereof.
36. The use of any one of claims 22-33, wherein the at least one inhibitor is chosen from ABT737 and pharmaceutically acceptable salts thereof.
37. The use of any one of claims 22-33, wherein the at least one inhibitor is chosen from A-1331852 and pharmaceutically acceptable salts thereof.
38. The use of any one of claims 22-37, wherein the at least one spliceosome modulator is formulated for intravenous, oral, subcutaneous, or intramuscular administration.

39. The use of any one of claims 22-38, wherein the at least one spliceosome modulator is formulated for oral administration.
40. The use of any one of claims 22-39, wherein the at least one inhibitor is formulated for intravenous, oral, subcutaneous, or intramuscular administration.
41. The use of any one of claims 22-40, wherein the at least one inhibitor is formulated for oral administration.
42. The use of any one of claims 22-41, wherein the at least one spliceosome modulator is to be administered simultaneously with the at least one inhibitor.
43. The use of any one of claims 22-41, wherein the at least one spliceosome modulator is to be administered sequentially with the at least one inhibitor.
44. The use of any one of claims 22-41, wherein the at least one spliceosome modulator is to be administered separately with the at least one inhibitor.
45. The use of any one of claims 22-44, wherein said cancer is chosen from myelodysplastic syndrome, multiple myeloma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, chronic myelomonocytic leukemia, acute myeloid leukemia, colon cancer, pancreatic cancer, endometrial cancer, ovarian cancer, breast cancer, uveal melanoma, gastric cancer, cholangiocarcinoma, and lung cancer.
46. The use of claim 45, wherein said cancer is lung cancer.
47. The use of claim 46, wherein said lung cancer is chosen from non-small cell lung carcinoma and small cell lung carcinoma.
48. The use of any one of claims 22-44, wherein said cancer is chosen from hematological cancers.
49. The use of claim 48, wherein said hematological cancer is chosen from acute lymphoblastic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic

myelogenous leukemia, chronic myelomonocytic leukemia, acute monocytic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, myelodysplastic syndrome, and multiple myeloma.

50. The use of any one of claims 22-44, wherein said cancer is chosen from solid tumors.

51. The use of claim 50, wherein said solid tumor is chosen from breast cancer, pancreatic cancer, prostate cancer, colon or colorectal cancer, lung cancer, gastric cancer, cervical cancer, endometrial cancer, ovarian cancer, cholangiocarcinoma, glioma, and melanoma.

52. The use of any one of claims 22-44, wherein said cancer is chosen from MCL1-dependent cancers.

53. The use of claim 52, wherein said MCL1-dependent cancer is selected from acute lymphoblastic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, acute monocytic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, myelodysplastic syndrome, multiple myeloma, lung cancer, breast cancer, pancreatic cancer, prostate cancer, colon or colorectal cancer, gastric cancer, cervical cancer, endometrial cancer, ovarian cancer, cholangiocarcinoma, glioma, and melanoma.

54. The use of any one of claims 22-44, wherein said cancer is positive for one or more mutations in a spliceosome gene or protein.

55. The use of claim 54, wherein said spliceosome gene or protein is chosen from splicing factor 3B subunit 1 (SF3B1), U2 small nuclear RNA auxiliary factor 1 (U2AF1), serine/arginine-rich splicing factor 2 (SRSF2), zinc finger (CCCH type) RNA-binding motif and serine/arginine rich 2 (ZRSR2), pre-mRNA-processing-splicing factor 8 (PRPF8), U2 small nuclear RNA auxiliary factor 2 (U2AF2), splicing factor 1 (SF1), splicing factor 3a subunit 1 (SF3A1), PRP40 pre-mRNA processing factor 40 homolog B (PRPF40B), RNA binding motif protein

10 (RBM10), poly(rC) binding protein 1 (PCBP1), crooked neck pre-mRNA splicing factor 1 (CRNKL1), DEAH (Asp-Glu-Ala-His) box helicase 9 (DHX9), peptidyl-prolyl cis-trans isomerase-like 2 (PPIL2), RNA binding motif protein 22 (RBM22), small nuclear ribonucleoprotein Sm D3 (SNRPD3), probable ATP-dependent RNA helicase DDX5 (DDX5), pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 (DHX15), and polyadenylate-binding protein 1 (PABPC1).

56. The use of claim 55, wherein said spliceosome gene or protein is splicing factor 3B subunit 1 (SF3B1).